Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-blind study of repeat intravenous doses of GSK249320 in patients with stroke
2008-005041-33Phase 2Completed
- Sponsor
- GSK
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-blind trial of refanezumab in stroke, sponsored by GSK. Primary endpoints: Safety and tolerability of GSK249320, Immunogenicity of GSK249320 and 2 more. Started May 2009; status: completed.
02
Drugs
refanezumab
03
Conditions
stroke
Beyond the preview
Go deeper on 2008-005041-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005041-33.